Unmet Need / Invention Novelty: Current prostate-specific antigen (PSA)-based tests lack specificity in differentiating between aggressive and non-aggressive prostate cancer (PC), the latter of which does not require invasive intervention or treatment. Aggressive prostate cancer is therefore over-diagnosed and overtreated. There is an unmet need to identify serum biomarkers that can differentiate between aggressive and non-aggressive prostate cancer with better specificity.
Technical Details: Researchers at Johns Hopkins have identified and validated novel panels of serum biomarkers, through a comprehensive literature search, that can aid in the differentiation between aggressive and non-aggressive prostate cancer. The multivariate panels, in combination with the PSA-based Prostate Health Index (Phi) test, demonstrated superior diagnostic performance for aggressive prostate cancer. As such, this discovery may serve as an enhanced tool for prostate cancer staging and risk assessment for optimized treatment guidance.
Value Proposition:
• Multivariate panels of serum biomarkers with enhanced specificity to differentiate indolent and aggressive PC
• Improved diagnostic specificity in combination with the Phi test compared to Phi test or PSA test alone by 20% and 33% respectively.
Looking for Partners to: Develop & commercialize as novel multivariate panels for differentiation of aggressive prostate cancer
Stage of Development: Pre-Clinical
Data Availability: in vitro data, including panel validation data in aggressive and non-aggressive PC patient serum.
Inventors: Daniel Wan-Yu Chan, Zhen Zhang, Lori Jean Sokoll, Jin Song, Shiyong Ma, & Hui Zhang
Patent Status: Provisional patent application filed.
Publication(s)/Related Technology: Song & Ma et al. 2021. A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer. Theranostics, 11(13):6214-6624.
